Balachandran B, et al. - The researchers compared using early oral diazoxide or a placebo for small for gestational age (SGA) neonates with hyperinsulinaemic hypoglycaemia (HH), given a very common prevalence of HH in these subjects. This trial focused on SGA neonates born at least 32 weeks of gestation with HH during the first five days of life. The results obtained from this randomised, double-blind, placebo-controlled trial indicate that using oral diazoxide for SGA neonates with HH provided early hypoglycaemic control with no apparent adverse effects.